Adhesión real al dimetilfumarato en pacientes con esclerosis múltiple remitente-recurrenteOriginal Published on 2023-01-242024-09-05 Journal: Revista de neurologia [Category] update2024, [키워드] COVID-19 dimethyl fumarate Dimetilfumarato Disease-modifying therapy DMF Esclerosis múltiple recurrente-remitente Evidencia en el mundo real Real-world evidence Relapsing-Remitting Multiple Sclerosis Tratamiento modificador de la enfermedad [DOI] 10.33588/rn.76S01.2022296 PMC 바로가기 [Article Type] Original
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumabArticle Published on 2022-11-012022-11-15 Journal: Wiener medizinische Wochenschrift (1946) [Category] 바이오마커, 진단, [키워드] addition Autoimmunitiy brain tissue Central nervous system chronic inflammatory disease COVID-19 pandemic Demyelination disadvantage disease effective Evidence MRI Multiple multiple sclerosis neurodegeneration Neuroimmunology Patient primary mechanism Primary progressive multiple sclerosis provide Relapsing-Remitting Multiple Sclerosis Research T cell therapeutic Therapeutic approach Therapies therapy Treatment Trial [DOI] 10.1007/s10354-022-00939-w PMC 바로가기
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients오크렐리주맙 치료를 받은 재발-완화성 다발성 경화증 환자에서 단일 SARS-COV-2 백신 투여 후 혈청전환 감소Article Published on 2022-06-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval antibodies AZD1222 B-cell B-cells BNT162b2 CD20 COVID-19 COVID-19 vaccine detectable diminished dose Efficacy expected Humoral response IgG immunogenicity Immunoglobulin Immunoglobulin G individuals Luminex assay Ocrelizumab Odds ratio Patient patients predicted recipient recipients Relapsing-Remitting Multiple Sclerosis SARS-CoV-2 Seroconversion seroconverted single dose the patient undetectable vaccination Vaccine vaccine dose vaccine immunogenicity [DOI] 10.1177/13524585211046786 PMC 바로가기 [Article Type] Article
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort studyCOVID-19는 장기 재발 방출 다발성 경화증 임상 활동을 증가합니까?코호트 연구Observational Study Published on 2022-02-222022-09-10 Journal: BMC Neurology [Category] 임상, 치료기술, [키워드] Analysis association changes in clinical disease Cohort cohort study conducted Course COVID-19 COVID-19 diagnosis defined Demyelinating diseases detect disability Disease progression EDSS Evidence Expanded Disability Status Scale Final final analysis follow-up period hazard increase in initiated Logistic measure multiple sclerosis Neuroinflammation not achieved objective observational study progression Ratio Relapse Relapsing-Remitting Multiple Sclerosis Replication Research Result sensitivity analysis significant difference significantly statistical significance subject supplementary material survival survival analysis sustained while worsening [DOI] 10.1186/s12883-022-02590-9 PMC 바로가기 [Article Type] Observational Study
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort studyObservational Study Published on 2022-02-222022-10-27 Journal: BMC Neurology [Category] COVID-19, [키워드] Analysis association changes in clinical disease Cohort cohort study conducted Course COVID-19 COVID-19 diagnosis defined Demyelinating diseases detect Disease progression EDSS Evidence Final follow-up period hazard increase in initiated Logistic measure multiple sclerosis Neuroinflammation objective progression Ratio Relapsing-Remitting Multiple Sclerosis Replication Research Result significant difference significantly statistical significance subject supplementary material survival survival analysis sustained while worsening [DOI] 10.1186/s12883-022-02590-9 PMC 바로가기 [Article Type] Observational Study
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort studyObservational Study Published on 2022-02-222022-10-27 Journal: BMC Neurology [Category] Coronavirus, COVID-19, COVID19(2023년), Fulltext, MERS, SARS, [키워드] Analysis association changes in clinical disease Cohort cohort study conducted Course COVID-19 COVID-19 diagnosis defined Demyelinating diseases detect Disease progression EDSS Evidence Final follow-up period hazard increase in initiated Logistic measure multiple sclerosis Neuroinflammation objective progression Ratio Relapsing-Remitting Multiple Sclerosis Replication Research Result significant difference significantly statistical significance subject supplementary material survival survival analysis sustained while worsening [DOI] 10.1186/s12883-022-02590-9 PMC 바로가기 [Article Type] Observational Study
Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic표준 및 연장된 나탈리주맙 투여 간격 동안의 소모 증상: COVID-19 범유행의 경험Observational Study Published on 2021-10-152022-09-12 Journal: Journal of the neurological sciences [Category] MERS, SARS, 임상, 진단, [키워드] Affect changed COVID-19 COVID-19 pandemic Disease activity dosing interval evaluated experience Extended Extended interval dosing Individualized medicine intensity leukoencephalopathy mitigate Multiple multiple sclerosis Natalizumab New Norway observation outbreak Patient Prevalence Prevent Randomized controlled trials Receptor occupancy Relapsing-Remitting Multiple Sclerosis reported risk Support Symptom Symptoms treated patient Wearing-off. [DOI] 10.1016/j.jns.2021.117622 PMC 바로가기 [Article Type] Observational Study
Complications of COVID-19 Pneumonia and Multiple Sclerosis ExacerbationFamily/General Practice Published on 2021-08-272022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Autoimmune disease average Brain Complication coronavirus disease COVID COVID-19 COVID-19 pneumonia Demyelination disrupt DMARD Exacerbation Hospitalization immunological increased risk Infection inpatient admission Limited MS Multiple multiple sclerosis multiple sclerosis exacerbation multiple sclerosis flare-ups Neurological symptom occur Patient Pneumonia Relapsing-Remitting Multiple Sclerosis reported sclerosis severe COVID-19 shown steroid Stress subgroups Symptom management the disease The United States Transmission Treatment while worsened [DOI] 10.7759/cureus.17506 PMC 바로가기 [Article Type] Family/General Practice
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference CenterOriginal Research Published on 2021-08-232024-09-02 Journal: Frontiers in Neurology [Category] 대상포진, [키워드] annualized relapse rate disease-modifying treatment fingolimod highly-active multiple sclerosis Natalizumab Relapsing-Remitting Multiple Sclerosis [DOI] 10.3389/fneur.2021.699844 PMC 바로가기 [Article Type] Original Research
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19COVID-19 시기에 다발성 경화증에서 Ocrelizumab 연장된 간격 투여Observational Study Published on 2021-07-142022-09-11 Journal: Neurology® neuroimmunology & neuroinflammation [Category] 바이오마커, 임상, 진단, [키워드] accompanied association B-cell both groups CD19 class classification clinical clinical consequence clinical consequences Cohort control group coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic defined disability Disease activity dose Dosing Effectiveness evaluate evaluated Evidence evidence of Extended extended interval Follow-up in both group interquartile range interval Logistic regression median MRI multicenter cohort study Multiple multiple sclerosis multivariate multivariate logistic regression no evidence of Ocrelizumab pandemic Patient potential risk progression provide Relapsing-Remitting Multiple Sclerosis remained retrospective sclerosis stability standard interval Support time treatment regimen [DOI] 10.1212/NXI.0000000000001035 PMC 바로가기 [Article Type] Observational Study